DDC-02 / JW Pharma - LARVOL DELTA

JW Pharmaceutical Presents Preclinical Results and Global Development Strategy for DDC-02, a Novel Therapeutic Candidate for Rare Neurodevelopmental Disorders (Businesswire) - "Data presented at WODC USA 2026....The presentation featured data demonstrating the effects of DDC-02 across animal models of several rare neurodevelopmental disorders, including Pitt-Hopkins syndrome (PTHS), Fragile X syndrome (FXS), and Rett syndrome (RTT), each of which arises from distinct genetic causes. Across these models, DDC-02 consistently restored deficits in cognitive and behavioral function....JW Pharmaceutical is evaluating Pitt-Hopkins syndrome as the lead indication for DDC-02 and is targeting entry into global multi-regional clinical studies in 2028."

Preclinical • CNS Disorders • Fragile X Syndrome • Rare Diseases